Teva Releases Generic EpiPen in Limited Doses in the U.S. -- Update
2018年11月28日 - 2:04AM
Dow Jones News
By Colin Kellaher
Teva Pharmaceutical Industries Ltd. on Tuesday said its generic
version of Mylan N.V.'s EpiPen 0.3-milligram injector device for
life-threatening allergic reactions now is available in limited
doses in the U.S., at a list price of $300 for a two-pack.
The U.S. Food and Drug Administration in August approved Teva's
generic version of the EpiPen, the most widely sold such device in
the U.S., amid shortages of the emergency treatment.
EpiPens have been in short supply since at least May, with
problems stemming from regional supply disruptions and manufacturer
issues.
The FDA in August extended the expiration date of some lots of
EpiPen products by four months beyond the labeled expiration date
in a bid to mitigate the shortages. EpiPen has an approved 20-month
shelf life.
Mylan touched off a furor two years ago after price increases of
548% over about a decade drove the cost of the EpiPen to just above
$600 for a two-pack. Mylan introduced its own half-priced generic
version of the drug in 2016.
Teva said it expects an additional supply of its generic version
of the EpiPen, along with a generic version of the 0.15-milligram
EpiPen Jr, will be available next year.
Write to Colin Kellaher at colin.kellaher@wsj.com.
(END) Dow Jones Newswires
November 27, 2018 11:49 ET (16:49 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 6 2024 まで 7 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 7 2023 まで 7 2024
